Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance.

Show other versions (1)

<h4>Background</h4>Ceftobiprole is an advanced-generation cephalosporin with activity against methicillin-resistant Staphylococcus aureus, resistant pneumococci, and Enterobacterales. In a Phase 3 study in community-acquired bacterial pneumonia (CABP) performed prior to the current US Fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrew F Shorr, Mark E Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I Smart, Marc Engelhardt
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0326758
Tags: Add Tag
No Tags, Be the first to tag this record!
Search Result 1
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance

Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance by Andrew F. Shorr, Mark E. Jones, Silke Friedmann, Daniel Ionescu, Mikael Saulay, Jennifer I. Smart, Marc Engelhardt

Published 2025-01-01
Get full text
Article
Save to List
Saved in:
Show all versions (2)

Similar Items